Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

New study: Positive outcomes from gene therapy trial in patients with Parkinson's

A multi-center gene therapy trial for patients with advanced Parkinson's disease demonstrated reduced symptoms of the progressive movement disorder, according to a new study published in Lancet Neurology.

17 Mar 2011

Researchers discover 3-D structure of key biological receptor

Researchers have solved the three-dimensional structure of a key biological receptor. The finding has the potential to speed drug discovery in many areas, from arthritis to respiratory disorders to wound healing, because it enables chemists to better examine and design molecules for use in experimental drugs.

16 Mar 2011

Malaria drug shrinks, slows resistant pancreatic tumors

Dana-Farber Cancer Institute scientists report they have shrunk or slowed the growth of notoriously resistant pancreatic tumors in mice, using a drug routinely prescribed for malaria and rheumatoid arthritis.

16 Mar 2011

Plexxikon selects Clinipace to manage 4 clinical trials for RA treatment

Clinipace Worldwide, a global digital clinical research organization, announced today that Plexxikon Inc., a leader in the structure-guided discovery and development of novel small molecule pharmaceuticals to treat human disease, has selected Clinipace to manage all aspects of four clinical trials comprising a Phase 1 healthy volunteer study, a Phase 1b rheumatoid arthritis study, and two phase 2 oncology studies.

16 Mar 2011

New study identifies 15 genetic regions underlying primary biliary cirrhosis

Researchers have provided new clues into the genetics underlying a chronic form of liver disease, called primary biliary cirrhosis, which can lead to transplant surgery for patients.

14 Mar 2011

Study to identify drug targets for rheumatoid arthritis patients not responding to anti-TNF therapies

GNS Healthcare, Inc., (GNS) the leading healthcare analytics company focused on enabling personalized medicine to improve human health, today announced the publication of results from a study focused on identifying novel drug targets for the one-third of rheumatoid arthritis patients who do not respond to leading anti-TNF therapies.

11 Mar 2011

Sanofi-aventis, Regeneron announce results of VEGF Trap Phase III trial in second-line NSCLC

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced results from the Phase III VITAL trial evaluating the investigational agent aflibercept (VEGF Trap) for the second-line treatment of non-small cell lung cancer (NSCLC).

11 Mar 2011

Researchers create protein molecule for new anti-inflammatory therapies

Researchers from across multiple disciplines at NYU Langone Medical Center created a new protein molecule derived from the growth factor progranulin may provide the basis for new therapies in inflammatory diseases, such as rheumatoid arthritis, according to a study published in the March 10, 2011 issue of Science.

11 Mar 2011

Idera reports $6.0 million net loss for fourth quarter 2010

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2010.

10 Mar 2011

Santarus commences SAN-300 Phase I clinical study to treat inflammatory diseases

Santarus, Inc., a specialty biopharmaceutical company, today announced that it has initiated a Phase I clinical study with SAN-300, its anti-VLA-1 antibody.

10 Mar 2011

ALR commits funding for new study to identify lupus susceptibility genes in multiple ethnicities

The Alliance for Lupus Research (ALR) – the world's largest private funder of lupus research – today announced funding of an important new study to identify lupus susceptibility genes in multiple ethnicities including African Americans, who are three times more likely than Caucasians to have the disease.

10 Mar 2011

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011

Karolinska Institutet, LUMC coordinate largest European program on RA

Karolinska Institutet in Sweden and Leiden University Medical Center (LUMC) in the Netherlands will coordinate the largest European program so far, aimed at developing new therapies against Rheumatoid Arthritis (RA). The program, named Be The Cure (BTCure), is funded for the next 5 years by the Innovative Medicines Initiative (IMI), and will bring together academic rheumatology research and research in pharmaceutical companies in Europe.

9 Mar 2011

Recent rituximab trial with TNF inhibitors reports no new safety risks in patients with RA

A recent trial of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis found the safety profile to be consistent with other RA trials with TNF inhibitors.

8 Mar 2011

Arthritis handle kitchen tool for RA sufferers

His design has earnt a spot on the first-round shortlist of one of the world's most prestigious design competitions - the Australian Design Award/James Dyson Award.

8 Mar 2011

North Shore-LIJ launches new prenatal quality initiative

Having a child is a life event that is equal parts magic and fear. Will the baby be healthy? Will labor and delivery pose challenges? Are there ways to reduce the risk for adverse events? Hospital obstetrical units face these questions round-the-clock.

8 Mar 2011

Dr Russell Wallis, Reader and RCUK Academic Fellow to give Frank May Prize Lecture 2010

The Frank May Prize Lecture 2010, entitled 'Fishing for Complement: innate targeting of microbial pathogens', will be given by Dr Russell Wallis, Reader and RCUK Academic Fellow in the Department of Infection, Immunity and Inflammation, and Department of Biochemistry.

5 Mar 2011

Pfizer's ORAL Sync Phase 3 study of tofacitinib in moderate-to-severe RA meets primary endpoints

Pfizer Inc. today announced that the ORAL Sync Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor, being studied in moderate-to-severe rheumatoid arthritis, met its primary endpoints by showing statistically significant changes versus placebo in reducing signs and symptoms of RA, as measured by ACR20 response rates at six months; in improving physical function, as measured by mean change in HAQ DI at three months; and in reaching DAS28-4 <2.6 at six months.

5 Mar 2011

Triptolide isolated from Chinese medicinal plant blocks gene control machinery in cells

Researchers at the Johns Hopkins School of Medicine have discovered that a natural product isolated from a traditional Chinese medicinal plant commonly known as thunder god vine, or lei gong teng, and used for hundreds of years to treat many conditions including rheumatoid arthritis works by blocking gene control machinery in the cell. The report, published as a cover story of the March issue of Nature Chemical Biology, suggests that the natural product could be a starting point for developing new anticancer drugs.

4 Mar 2011

Protalex initiates enrollment in 3rd cohort of PRTX-100 Phase 1b dose escalation clinical study in RA

Protalex, Inc, a clinical stage biopharmaceutical company which is engaged in developing a class of drugs for treating autoimmune and inflammatory diseases, today announced enrollment of the first patients in the 3rd cohort of its ongoing multicenter Phase 1b dose escalation clinical study of PRTX-100 in adult patients with active Rheumatoid Arthritis (RA) being conducted in South Africa. The dose was increased by a factor of two from the 2nd cohort.

3 Mar 2011

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

New study: Positive outcomes from gene therapy trial in patients with Parkinson's

Researchers discover 3-D structure of key biological receptor

Malaria drug shrinks, slows resistant pancreatic tumors

Plexxikon selects Clinipace to manage 4 clinical trials for RA treatment

New study identifies 15 genetic regions underlying primary biliary cirrhosis

Study to identify drug targets for rheumatoid arthritis patients not responding to anti-TNF therapies

Sanofi-aventis, Regeneron announce results of VEGF Trap Phase III trial in second-line NSCLC

Researchers create protein molecule for new anti-inflammatory therapies

Idera reports $6.0 million net loss for fourth quarter 2010

Santarus commences SAN-300 Phase I clinical study to treat inflammatory diseases

ALR commits funding for new study to identify lupus susceptibility genes in multiple ethnicities

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Karolinska Institutet, LUMC coordinate largest European program on RA

Recent rituximab trial with TNF inhibitors reports no new safety risks in patients with RA

Arthritis handle kitchen tool for RA sufferers

North Shore-LIJ launches new prenatal quality initiative

Dr Russell Wallis, Reader and RCUK Academic Fellow to give Frank May Prize Lecture 2010

Pfizer's ORAL Sync Phase 3 study of tofacitinib in moderate-to-severe RA meets primary endpoints

Triptolide isolated from Chinese medicinal plant blocks gene control machinery in cells

Protalex initiates enrollment in 3rd cohort of PRTX-100 Phase 1b dose escalation clinical study in RA

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in